DSIP — delta sleep-inducing peptide — is one of the older entries in the neuropeptide literature, and its name is also the source of a persistent misconception about what it is. The compound was named for an electroencephalogram (EEG) pattern recorded in animals, not for anything it does in a person. This overview covers what DSIP is at the molecular level, where it came from, and what the published research actually measured, framed strictly as what studies reported in their experimental models.
What DSIP is
DSIP is a small neuropeptide — specifically a nonapeptide, meaning a chain of nine amino acids. Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), which has been confirmed by amino-acid analysis and sequence determination of the isolated material and by synthesis of the matching peptide. It is a short, linear, unblocked chain with a free amino terminus and a free carboxyl terminus, and a molecular weight in the region of roughly 850 daltons.
The amino-acid makeup is unremarkable on its own — the residues are all standard, and several of them (the glycines and alanines) are among the smallest and most common in biology. What made the molecule notable was not its chemistry but the experimental context in which it was first detected. It is best described as a neuromodulatory peptide: a substance studied for its capacity to influence the activity of nervous-system tissue rather than to act as a classical hormone or enzyme.
- Class: linear nonapeptide (nine amino acids).
- Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE).
- Approximate molecular weight: on the order of 850 daltons.
How it was discovered
DSIP was first isolated in the mid-1970s by the Schoenenberger–Monnier research group in Basel, Switzerland. The experimental approach was unusual. The investigators induced a slow-wave EEG state in rabbits — in the original work, by low-frequency electrical stimulation of thalamic structures — and then collected and dialyzed the cerebral venous blood from those animals. From that dialysate they purified a peptide fraction that, when administered to recipient rabbits, was reported to reproduce the same EEG pattern.
In the 1977 report of this work, the group described isolating and characterizing the peptide and assigning it the name delta sleep-inducing peptide, after the delta-frequency EEG activity associated with the donor state (Schoenenberger et al., 1977). A follow-up paper completed the structural side of the story, presenting the amino-acid analysis, the nine-residue sequence, the chemical synthesis of that sequence, and a comparison confirming the synthetic peptide matched the natural isolate (Schoenenberger et al., 1978). The name has stuck for fifty years even though, as later authors emphasized, it encodes a conclusion the early data did not fully support.
What the research measured: delta-EEG and sleep models
The defining experiments measured EEG activity in animals, not subjective sleep in people. In the original characterization, intraventricular infusion of the peptide in rabbits was reported to increase slow-wave (delta-frequency) and spindle EEG activity relative to controls, under blinded conditions (Schoenenberger et al., 1977). The endpoint here is an electrophysiological recording — the amount and frequency of slow waves on the EEG trace — not a behavioral or self-reported outcome.
Subsequent work explored how the molecule could be modified. One study examined a phosphorylated analogue of DSIP infused intracerebroventricularly in unrestrained rats and reported increases in measured slow-wave sleep and paradoxical (REM) sleep relative to vehicle, with the phosphorylated form showing greater potency than the parent peptide in that model (Kimura et al., 1989). Again the relevant point is the framing: the study quantified scored sleep stages in instrumented rats, and reported a difference between treated and control animals.
Crucially, the literature on DSIP is not uniform. A broad review of the peptide’s characterization and properties catalogued effects reported across many laboratories — on EEG, on a range of physiological parameters, and on responses to stress — while noting the inconsistency between studies (Schoenenberger et al., 1984). Decades later, a review pointedly titled DSIP “a still unresolved riddle,” summarizing that even basic questions about its mechanism, its endogenous role, and the reproducibility of its sleep-related effects remained open (Kovalzon & Strekalova, 2006). For a research-overview reader, that unresolved status is the most honest single takeaway from the sleep literature.
Beyond sleep: other measured effects in models
Because the early reports described a peptide with diffuse central activity, later research examined endpoints well outside sleep. The Schoenenberger group’s own review described DSIP as having multivariate functions — that is, a range of effects measured across different physiological systems rather than a single tidy action (Schoenenberger et al., 1984).
A more recent example comes from a stroke model. In Sprague-Dawley rats subjected to focal cerebral ischemia by middle cerebral artery occlusion, intranasal administration of DSIP over several days was associated with faster recovery of motor function on rotarod testing compared with vehicle-treated animals, even though the measured infarct volume differed little between groups (Tukhovskaya et al., 2021). This is cited here only to illustrate the breadth of endpoints the peptide has been studied against; it is a measurement made in a rodent injury model, not a statement about any effect in a person.
- EEG endpoints — slow-wave and spindle activity recorded in rabbits (Schoenenberger et al., 1977).
- Scored sleep stages — slow-wave and paradoxical sleep measured in instrumented rats with a modified analogue (Kimura et al., 1989).
- Motor-recovery endpoints — rotarod performance measured in a rat stroke model (Tukhovskaya et al., 2021).
Why the name is misleading
The phrase “sleep-inducing” describes the EEG state of the donor rabbits, not a verified action in any species that received the purified peptide. The slow-wave EEG signature that gave DSIP its name is a correlate, and across half a century of follow-up the connection between that signature and a robust, reproducible sleep effect has remained contested in the literature (Kovalzon & Strekalova, 2006). When reading older sources that treat the name as a description of function, it is worth keeping the distinction in mind: DSIP is named after a recording, and what each study supports is whatever that study specifically measured — an EEG change, a scored sleep stage, a behavioral score — in its own model.
Frequently asked questions
What is DSIP?
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide (a nonapeptide) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was isolated in the mid-1970s from research on slow-wave EEG activity in rabbits and is studied as a neuromodulatory peptide.
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. The “delta” refers to the delta-frequency slow waves seen on the EEG of the animals from which the peptide was first isolated, not to a verified effect in the recipient.
What is the amino-acid sequence of DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), confirmed by amino-acid analysis and by synthesis of the matching peptide (Schoenenberger et al., 1978).
Where did DSIP come from?
It was isolated by the Schoenenberger–Monnier group in Basel, Switzerland, in the mid-1970s. They induced a slow-wave EEG state in rabbits, dialyzed the cerebral venous blood, and purified the peptide responsible for reproducing that EEG pattern in recipient animals (Schoenenberger et al., 1977).
What does the research on DSIP actually show?
The published studies report what was measured in laboratory models: increased slow-wave and spindle EEG activity in rabbits (Schoenenberger et al., 1977), increased scored slow-wave and REM sleep in rats given a phosphorylated analogue (Kimura et al., 1989), and a range of other physiological endpoints. Reviews note the results have been inconsistent across laboratories, and one called DSIP “a still unresolved riddle” (Kovalzon & Strekalova, 2006).
Is the “sleep-inducing” name accurate?
The name describes the EEG state of the donor animals rather than a reproducible action in recipients. The link between DSIP and a robust sleep effect has remained contested in the research literature for decades (Kovalzon & Strekalova, 2006).
References
- Schoenenberger GA, et al. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977. PMID: 265572.
- Schoenenberger GA, et al. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. 1978. PMID: 568769.
- Schoenenberger GA, et al. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984. PMID: 6548966.
- Kimura M, et al. The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats. Psychopharmacology (Berl). 1989. PMID: 2496423.
- Kovalzon VM, et al. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID: 16539679.
- Tukhovskaya EA, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021. PMID: 34500605.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
